Modern Diagnostic FY26 Results: Revenue Grows, Profit Declines Sharply

Modern Diagnostic and Research Centre Ltd reported ₹83.11 crore in revenue for the year ended March 31, 2026, a 6.63% increase from ₹77.95 crore in FY25. However, the company's net profit saw a significant decline of 41.71%, falling to ₹5.25 crore from ₹9.01 crore in the previous year. Earnings per share (EPS) also contracted by 57.51% to ₹3.48.

Reader Takeaway: Revenue growth shows expansion; rising costs pressure margins.

What just happened

Modern Diagnostic and Research Centre Ltd released its audited financial results for the fiscal year 2026. The company reported an increase in revenue from operations but experienced a substantial drop in net profit. This divergence was primarily attributed to a sharp rise in total expenses, which grew by approximately 18.5% year-over-year, outpacing the revenue growth.

Why this matters

The decline in net profit, despite revenue growth, signals potential margin pressures. Investors will be keen to understand the sustainability of current cost structures and the effectiveness of the company's strategies to improve profitability. The clean, unmodified audit opinion, however, provides a layer of confidence in the company's financial reporting.

The backstory

Modern Diagnostic and Research Centre Ltd was listed on the BSE SME Platform in January 2026. The company had raised gross IPO proceeds of ₹36.89 crore. A significant portion of these funds was earmarked for the purchase of medical equipment and for working capital needs.

What changes now

The company is actively deploying its IPO funds. As of March 31, 2026, ₹6.46 crore of the ₹20.69 crore proposed for medical equipment had been utilized, with ₹14.23 crore remaining. Similarly, ₹4.92 crore of the ₹8.00 crore allocated for working capital had been used. Investors will be looking for these investments to translate into improved operational efficiency and profitability in the future.

Risks to watch

The primary concern is the significant rise in operating expenses, particularly employee benefit expenses (up to ₹22.98 crore) and other expenses (up to ₹25.93 crore), which have eaten into profits. Additionally, the substantial unutilized IPO funds, especially for medical equipment, present a risk if not deployed effectively to drive growth and efficiency.

Peer comparison

Information on specific peers and their comparative financial performance for FY26 is not detailed in the filing. However, for diagnostic chains, revenue growth is typically accompanied by improved margins through economies of scale and operational efficiencies. Modern Diagnostic's current performance indicates a deviation from this trend, highlighting its specific cost challenges.

Context metrics (time-bound)

• Revenue from Operations: Increased 6.63% to ₹83.11 crore in FY26 (from ₹77.95 crore in FY25).
• Net Profit: Decreased 41.71% to ₹5.25 crore in FY26 (from ₹9.01 crore in FY25).
• Total Expenses: Increased from ₹65.93 crore in FY25 to ₹78.15 crore in FY26.
• IPO Proceeds Utilized (as of Mar 31, 2026): ₹6.46 crore for medical equipment, ₹4.92 crore for working capital.

What to track next

Investors should closely monitor the company's next quarterly results to observe if the increased operating expenses can be managed effectively. The pace and impact of the remaining IPO fund utilization, particularly for medical equipment, will be crucial for future margin expansion and profitability improvement. No dividend was declared for FY26.